Plains Venture PartnersPlains Venture PartnersPlains Venture PartnersPlains Venture Partners
  • About
  • Portfolio
  • Team
  • Investor Login

i2E leads $1.2 million investment in Simergent, LLC

    Home News i2E leads $1.2 million investment in Simergent, LLC
    NextPrevious

    i2E leads $1.2 million investment in Simergent, LLC

    By sarah | News | 0 comment | 25 October, 2017 | 1

    Contact: Sarah Seagraves,
    Senior VP for Marketing
    (405) 813-2403
    sseagraves@i2E.org

    Simergent has developed an easy-to-use, affordable dialysis device for patients suffering from kidney failure

    OKLAHOMA CITY — i2E, Inc., recently led a $1.2 million investment round in Norman-based Simergent, LLC, a startup company that developed a peritoneal dialysis device that is affordable and easy to use.

    The investment round included $500,000 from the i2E-managed Oklahoma Seed Capital Fund, along with $119,000 from the SeedStep Angels, an Oklahoma investment group founded and managed by i2E. Other investors contributed the remaining $581,000.

    Peritoneal dialysis is a technology for filtering toxins out of the blood of people whose kidneys have failed. It is an alternative to hemodialysis, which is the most prevalent dialysis method by far in the United States.

    Simergent intends to use the investment funding for multiple initiatives that will advance the company and its technology, said Steve Lindo, co-founder and CEO.

    “This funding will provide the necessary resources for Simergent to expand our team of engineers, enhance the device’s design, and perform patient-centered activities required for regulatory approvals,” Lindo said. “We are grateful to i2E and all our high quality investors. Nephrologists around the globe are excited about the prospect of our Archimedes dialysis device, which provides significant cost reduction for home dialysis while the patient sleeps, thus allowing patients to live a normal life rather than traveling to a dialysis clinic three days per week.”

    The Oklahoma Seed Capital Fund is a state-appropriated investment fund managed by i2E through the Oklahoma Center for the Advancement of Science and Technology.

    The SeedStep Angels group was founded by i2E in 2009 and is now the state’s largest angel investment group with more than 50 members and chapters in Oklahoma City, Tulsa, Ardmore and Muskogee.

    About Simergent

    Founded in 2014, Simergent provides a solution to the world-wide problem of kidney failure. It created an affordable technology to bring peritoneal dialysis to patients in emerging countries around the world. Peritoneal dialysis is an alternative to hemodialysis, which is the most prevalent dialysis method by far in the United States. In peritoneal dialysis, there is no blood and no needles involved. Instead, the patient has a surgically implanted port in their abdomen and a machine delivers a sugar and electrolyte solution into their abdomen. The solution delivered by peritoneal dialysis draws wastes, toxins, and extra fluid from the tiny blood vessels in the peritoneal membrane , which is then drained from the patient.

    About i2E, Inc.

    With offices in Oklahoma City and Tulsa, OK, i2E’s nationally recognized services include business expertise and funding for Oklahoma’s emerging small businesses. i2E has more than $50 million of investment capital under management. www.i2E.org

    Oklahoma Seed Capital Fund, SeedStep Angels, Simergent, Steve Lindo

    Related Post

    • Norman’s IMMY has global impact, despite humble beginnings

      By sarah | 0 comment

      By Scott Meacham Copyright © 2019 The Oklahoman Sean and Scott Bauman, CEO and chief operating officer of biotechnology company IMMY, literally grew up in the family business. “There isn’t a job that my brotherRead more

    • Oklahoma’s bioscience prowess busy making a difference worldwide

      By sarah | 0 comment

      By Kevan Goff-ParkerCopyright © 2019 The Oklahoman Greater Oklahoma City Chamber Manager of Innovation and Entrepreneurship Evan Fay said he believes some people may be caught off-guard by Oklahoma’s growing bioscience prowess. He made hisRead more

    • Ascend BioVentures helps determine right path for health care discoveries

      By sarah | 0 comment

      By Scott Meacham Copyright © 2019, The Oklahoman It’s really difficult to invent new drug therapies. Research and development can take decades. Once a potential drug appears viable, testing for safety and efficacy adds moreRead more

    • OSU delegates share future bioscience innovations with leaders

      By sarah | 0 comment

      By Kevan Goff-Parker Copyright © 2019, The Oklahoman PHILADELPHIA — Three Oklahoma State University researchers this week have been connecting face-to-face with some of the world’s top bioscience companies during the 2019 BIO International ConventionRead more

    • Delegation Sharing Oklahoma’s Good News Bioscience Story at BIO International Convention

      By sarah | 0 comment

      By Kevan Goff-Parker Copyright ©2019, The Oklahoman PHILADELPHIA — More than 40 Oklahoma bioscience and industry experts from a wide array of fields are busy telling global industry leaders about the state’s successes in theRead more

    Leave a Comment

    Cancel reply

    You must be logged in to post a comment.

    NextPrevious

    Investor Login

    • Disclaimer & Disclosure

    Oklahoma City Location

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305

    Click HERE for directions.

    Tulsa Location

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592

    Click HERE for directions.

    • Disclaimer & Disclosure
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • About
    • Portfolio
    • Team
    • Funds
    • Investor Login
    Plains Venture Partners